Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight loss of up to 20% over 52 weeks in individuals living with obesity or overweight but without type 2 diabetes. For those with diabetes, the average weight loss reached 17%.
William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...
The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over one year for patients who were obese or overweight without diabetes. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback